Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

2(40%)

Results Posted

67%(2 trials)

Phase Distribution

Ph early_phase_1

20%

Ph phase_1

20%

Ph phase_3

20%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(3)

Detailed Status

Completed3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Early Phase 11 (20.0%)

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 31 (20.0%)

Trials by Status

completed360%

recruiting240%

Recent Activity

2 active trials

Showing 5 of 5

recruitingphase_2

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

NCT04616456

Clinical Trials (5)

Showing 5 of 5 trials

NCT04297683Phase 2

HEALEY ALS Platform Trial - Master Protocol

Recruiting

NCT05184569Phase 1

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

Recruiting

NCT03952806Phase 3

Study of BHV-3241 in Participants With Multiple System Atrophy

Completed

NCT04436510Phase 2

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Completed

NCT04616456Early Phase 1

Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5